Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV).
about
Human pluripotent stem cells for modelling human liver diseases and cell therapyMapping full-length porcine endogenous retroviruses in a large white pigAbsence of replication-competent human-tropic porcine endogenous retroviruses in the germ line DNA of inbred miniature Swine.Pre-screening of miniature swine may reduce the risk of transmitting human tropic recombinant porcine endogenous retroviruses.Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection.Pig endogenous retroviruses and xenotransplantation.Influence of chitosan nanofiber scaffold on porcine endogenous retroviral expression and infectivity in pig hepatocytesGenomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine.Identification of receptors for pig endogenous retrovirus.Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.Prospects for extracorporeal liver support.Xenotransplantation: infectious risk revisited.Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus.Xenotransplantation and risks of zoonotic infections.Pigs taking wing with transposons and recombinases.Polymerase chain reaction in detection of porcine endogenous retrovirus (PERV) from porcine tissuesLiver support systems: promise and reality.Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation.Absence of replication of porcine endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with prolonged pig cell microchimerism after pig-to-baboon xenotransplantation.Xenotransplantation of islet cells: what can the non-human primate model bring for the evaluation of efficacy and safety?First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 5: recipient monitoring and response plan for preventing diseasComparison of porcine endogenous retroviruses infectious potential in supernatants of producer cells and in cocultures.Differential resistance to cell entry by porcine endogenous retrovirus subgroup A in rodent species.Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine.Infection of nonhuman primate cells by pig endogenous retrovirus.Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines.Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity.Porcine endogenous retrovirus (PERV) and its transmission characteristics: a study of the New Zealand designated pathogen-free herd.AN69 hollow fiber membrane will reduce but not abolish the risk of transmission of porcine endogenous retroviruses.Some morphological, growth, and genomic properties of human cells chronically infected with porcine endogenous retrovirus (PERV).Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy.Porcine endogenous retroviral nucleic acid in peripheral tissues is associated with migration of porcine cells post islet transplant.Miscellaneous.PERV inactivation is necessary to guarantee absence of pig-to-patient PERVs transmission in xenotransplantation.Why was PERV not transmitted during preclinical and clinical xenotransplantation trials and after inoculation of animals?Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs.Detection of porcine endogenous retrovirus (PERV) viremia in diseased versus healthy US pigs by qualitative and quantitative real-time RT-PCR.Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver.PERVading strategies and infectious risk for clinical xenotransplantation
P2860
Q27005360-A5981860-3041-4667-937D-A922FCBE5014Q30763809-0F32D052-1A54-4819-90CB-0F428D0B9E75Q31047713-DB7B609C-554B-4B84-B59E-46B2B0FA5319Q33284134-819D46ED-B727-48DB-ADCD-F7449FCFAC9FQ34545753-73E083AC-D396-4F54-89A6-3E3A09D741B6Q34680921-7A85AF2E-61D0-455A-891D-772B2DAA5799Q35065329-10992B66-9C1E-4EF3-B1A9-F342E7A2ABE0Q35129081-A80C2921-81F3-411A-9B52-E51E9511E2F3Q35144188-02B9E579-59A9-46D2-8581-F7221A168A5AQ35451131-936F54B3-F0DD-4B9F-9AB1-38D7CD9931F0Q35596562-D1EAACDC-AD1F-482E-B975-7016487B0373Q35861536-4421CD1D-8BD0-408D-8F8A-1DD8E798386BQ35910576-46DFE15B-11C3-4FEF-825B-0B90776A6099Q35932379-434A3392-EC13-4EA1-8C4B-45BA799476C6Q36187528-AB189D09-9455-4122-A33D-587909065172Q36255714-E3EE6DB5-7D00-4F44-A03D-FD354D56CDD1Q36335206-1163883C-AD88-4A1B-9F25-76AACA3AD7ACQ36684565-FA36E7BB-374E-4DBB-A713-B5C6135A4E3AQ36994608-03721CA6-0D29-4469-805B-89E401597C6BQ38443042-FB3CF49A-3BB0-4867-9125-DA1F5246733CQ38751243-21CD3F55-546E-4498-9D42-DC203B3C5CCEQ39032399-FC562235-EF50-49C0-8422-4B922707A8B6Q39226651-1F7D35C9-C622-4B6E-A32F-0C611DC1FB49Q39321537-C71D14C7-1BD8-4567-9FFA-660A99ABE2F1Q39592833-CA9062B7-9DA7-4DA7-9370-F8899596E136Q39595254-B8BCBAE5-4CC9-4AFF-935B-812489A88F6BQ39685877-48D3ADF5-A146-412A-8D23-A2509DA527B9Q40000135-93DC938F-A820-4FEE-9254-715E1FC44575Q40030013-2FF061E5-97E5-43A1-A4EF-B3369B7C4DCEQ40321687-2EDA6791-CA2A-4E6F-9BC5-19E3E23342E5Q40618150-F02E0216-E6B5-458D-8FF3-DC4E1B9556B4Q42439025-92816611-BF1D-4874-AD0A-FA8114281989Q47347255-5EDDAFFE-1ED1-4C98-B62D-0C98EBC01ABBQ48202240-9A54A5F3-5086-4BBB-BB97-EE632EBE7235Q48243013-B052B808-05A9-49B8-9F2B-3775375EC248Q52806116-4091F0F1-7B7F-4719-9EB0-E57776D47987Q52919756-EDD27FE5-7F12-4E0C-9E3B-BA64CCAFF951Q54383596-E56408EE-69E9-45BF-BC6D-3579E651A95CQ54397281-21414DBB-2529-433D-B139-F1A93177007FQ58766476-1BE17B3E-6C97-4FE0-A25B-4065A3020D08
P2860
Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV).
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Productive infection of primar ...... endogenous retrovirus (PERV).
@en
Productive infection of primary human endothelial cells by pig endogenous retrovirus
@nl
type
label
Productive infection of primar ...... endogenous retrovirus (PERV).
@en
Productive infection of primary human endothelial cells by pig endogenous retrovirus
@nl
prefLabel
Productive infection of primar ...... endogenous retrovirus (PERV).
@en
Productive infection of primary human endothelial cells by pig endogenous retrovirus
@nl
P2093
P2860
P1433
P1476
Productive infection of primar ...... endogenous retrovirus (PERV).
@en
P2093
Arseniev L
Haverich A
Patience C
Steinhoff G
Takeuchi Y
Winkler ME
P2860
P304
P356
10.1034/J.1399-3089.2000.00052.X
P577
2000-05-01T00:00:00Z